Description
| MOTS C 20MG | |
|---|---|
| SKU | CP_MOTS_C_20MG_3ML_VIAL |
| CATEGORY | Lyophilized Peptide |
| CAS | 1627580-64-6 |
| VIAL SIZE | 3 mL |
| FORM | LYOPHILIZED POWDER |
| MOLECULAR WEIGHT | 2174.6 g/mol |
| SEQUENCE | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg |
| MOLECULAR FORMULA | C101H152N28O22S2 |
| ITEM ID | 4315 |
A 2026 study characterized MOTS-c as an amphipathic, cationic peptide with direct antibacterial activity. In vitro, MOTS-c targeted Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA) membranes via its hydrophobic and cationic domains. In a murine acute peritonitis model, MOTS-c neutralized MRSA infectivity. In human monocyte cultures, interferon-γ, lipopolysaccharides, and differentiation signals each induced endogenous MOTS-c expression. Exogenous MOTS-c applied during primary mouse monocyte differentiation reprogrammed cells into macrophages with distinct transcriptomic signatures related to antigen presentation and interferon signaling, with shifted metabolic profiles and altered bacterial clearance capacity [1].
